(VIANEWS) – The Market ended the session with BIOSENIC (BIOS.BR) rising 9.81% to €0.12 on Monday while BEL 20 jumped 0.16% to €3,805.96.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.38.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be oversold (<=20).
More news about BIOSENIC (BIOS.BR).
